Navigation Links
Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
Date:2/1/2010

ABBOTT PARK, Ill. and CASTRES, France, Feb. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.  cMet protein plays a role in the progression of a range of solid tumors including, prostate, lung and gastric cancers and mediates resistance to chemotherapy.  As part of the agreement, the companies also intend to collaborate on research to explore next-generation cMet antibodies.  

"cMet is a compelling cancer target and the early research on this compound looks promising," John Leonard, M.D., senior vice president, global research and development, Abbott. "We look forward to adding to our strong oncology pipeline, which includes exploration of multiple mechanisms to treat cancer."

H224G11 works by specifically binding to cMet protein and interrupting the signaling pathway, which leads to cancer cell death and the prevention of tumor growth. The antibody also inhibits cancer cell migration and angiogenesis.  

"Using the strengths of its dedicated research team in biotechnology, Pierre Fabre SA has been able to develop potent and protein specific inhibitors of the cMet receptor. We are delighted to partner this important asset with Abbott scientists," declared Jean-Pierre Garnier, Chief Executive Officer of Pierre Fabre SA.

Under the terms of the collaboration and license agreement, Abbott will lead the development and commercialization of monoclonal antibodies targeting the cMet receptor. Pierre Fabre SA will receive an initial $25 million upfront payment and research funding to support further discovery efforts for two years. Additional terms of the agreement, including milestones and royalty payments, remain confidential.

About Pierre Fabre

Pierre Fabre SA is the second largest independent French Pharmaceutical company with a 2009 turnover of euro 1.8 billion. It employs around 10,000 people, including 1,400 employees dedicated to R&D activities. In 2009, Pierre Fabre Medicament dedicated over 30% of its annual turnover to R&D in major therapeutic fields.

To learn more about Pierre Fabre SA, please refer to the company's Web site at www.pierre-fabre.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

RELATED LINKS
http://www.abbott.com
http://www.pierre-fabre.com

'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
2. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
3. Abbott Completes Visiogen Acquisition
4. Abbott Cuts Use of Oil and Coal by 35 Percent
5. Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
6. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
7. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
8. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
9. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
10. New Data for Abbotts TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
11. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Ambulances announces its first delivery in the state of ... Emergency Medical Services (EMS) consisting of four vehicles: three ... Emergency Vehicles in Lecanto, FL , USA, ... the latest in Demers, ongoing expansion of sales.  ... --> Benoit LaFortune , Executive Vice President at Demers. ...
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. announced today that it ... the safety and effectiveness of the WEB™ Aneurysm Embolization ... aneurysms.  Prof Laurent Spelle , MD, Head of ... France and Principal Investigator of the CLARYS ... and Germany.  Although patients with ruptured aneurysms ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... of the Pittsburgh metro area, celebrates the beginning of the latest charity campaign ... develop social skills through art. Donations to this worthy cause are currently being ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the ... print component of “Revolutionizing Cancer Care” is distributed within the February 12 issue ... with a circulation of approximately 250,000 copies and an estimated readership of 750,000 ...
(Date:2/12/2016)... ... 2016 , ... A lot has been reported about the fitness routines of ... health and wellness resources most Americans could ever dream of having at their disposal. ... as frenetic as the U.S. President. , In honor of President’s Day on ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for ... of the Peety PoppersTM series, sign language translation is featured in the top right ... wellness in Peety PoppersTM lessons has a sign language translator to teach kids the ...
Breaking Medicine News(10 mins):